Business Context and Reporting Period
This Form 6-K filing covers the month of June 2026 for XTL Biopharmaceuticals Ltd., an Israeli advanced biotechnology company. The report details the consummation of a strategic acquisition and a concurrent private placement financing transaction.
Key Financial Metrics and Transaction Details
- Acquisition: XTL acquired approximately 83.40% of Psyga Bio Ltd. (a developer of psychedelic and functional mushroom products) on a fully diluted basis.
- Consideration: The acquisition was funded via the issuance of unregistered American Depositary Shares (ADSs) representing up to approximately 33.36% of XTL's post-transaction share capital.
- Contingent Consideration: Psyga Bio shareholders are eligible for additional ADSs (or warrants) representing up to an aggregate of 25% of XTL's share capital upon achieving three clinical and commercial milestones.
- Private Placement: The company raised US$1,500,000 at a price of US$2.70 per ADS.
- Warrant Structure: Investors received 1.2 Series A Warrants (exercise price US$2.70, reducible to US$1.70) and 1.2 Series B Warrants (exercise price US$5.00, reducible to US$2.50), each with a five-year term.
- Corporate Governance: Psyga Bio shareholders appointed one representative to XTL's six-member board of directors.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt levels.
Material Changes
The primary material change is the expansion of XTL's asset portfolio through the acquisition of Psyga Bio, shifting focus toward psychedelic and functional mushroom therapeutics. Additionally, the company's capital structure has changed significantly due to the issuance of new ADSs and warrants, resulting in substantial dilution to existing shareholders.
Outlook, Risks, and Contingencies
- Strategy: The transaction aligns with XTL's strategy to acquire high-potential IP-based assets.
- Related Party Transaction: The deal was approved as an interested party transaction under Israeli law because Mr. Alex Rabinovich, a Psyga Bio shareholder, is also an XTL director holding approximately 24.9% of XTL's capital.
- Future Financing Risks: The private placement agreement includes provisions for Series C Warrants to be issued in connection with a subsequent down-round financing if the price per ADS falls below the current purchase price.
- Contingencies: Future equity issuance is contingent upon the achievement of specific clinical, commercial, and stock price milestones.
Investor Verification Checklist
- Verify the exact number of ADSs issued for the acquisition and the private placement to calculate total post-transaction share count and dilution.
- Confirm the specific clinical and commercial milestones required to trigger the additional 25% equity issuance to Psyga Bio shareholders.
- Review the full terms of the Series A and Series B warrants, including the specific conditions for price reduction.
- Assess the financial health and intellectual property portfolio of Psyga Bio to validate the acquisition's strategic value.
- Check for any updated cash balance or liquidity position following the US$1.5 million raise.